Targeting Cellular and Tissue HIV Reservoirs With Toll-Like Receptor Agonists
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting Cellular and Tissue HIV Reservoirs With Toll-Like Receptor Agonists
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-10-15
DOI
10.3389/fimmu.2019.02450
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- HIV-1 reservoirs in urethral macrophages of patients under suppressive antiretroviral therapy
- (2019) Yonatan Ganor et al. Nature Microbiology
- TLR1/2 Specific Small‐Molecule Agonist Suppresses Leukemia Cancer Cell Growth by Stimulating Cytotoxic T Lymphocytes
- (2019) Xiaohong Cen et al. Advanced Science
- HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation
- (2019) Ravindra K. Gupta et al. NATURE
- Effects of 24 Week Toll-Like Receptor 9 Agonist Treatment in HIV-1+ Individuals
- (2019) Line K. Vibholm et al. AIDS
- Toll‐like receptor polymorphism in host immune response to infectious diseases: A review
- (2019) Suprabhat Mukherjee et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial
- (2019) Mansi Saxena et al. Frontiers in Immunology
- Influence of biological sex, age and HIV status in an in vitro primary cell model of HIV latency using a CXCR4 tropic virus
- (2018) Amanda B Macedo et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Eradication of HIV from Tissue Reservoirs: Challenges for the Cure
- (2018) Rebecca Rose et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Recent advances on Toll-like receptor 4 modulation: new therapeutic perspectives
- (2018) Lenny Zaffaroni et al. Future Medicinal Chemistry
- Anti-apoptotic Protein BIRC5 Maintains Survival of HIV-1-Infected CD4 + T Cells
- (2018) Hsiao-Hsuan Kuo et al. IMMUNITY
- Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells
- (2018) Szu-Han Huang et al. JOURNAL OF CLINICAL INVESTIGATION
- TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy
- (2018) So-Yon Lim et al. Science Translational Medicine
- Structure-based discovery of a specific TLR1–TLR2 small molecule agonist from the ZINC drug library database
- (2018) Zhipeng Chen et al. CHEMICAL COMMUNICATIONS
- TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs
- (2018) Liang Cheng et al. JOURNAL OF CLINICAL INVESTIGATION
- Diprovocims: A New and Exceptionally Potent Class of Toll-like Receptor Agonists
- (2018) Matthew D. Morin et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys
- (2018) Erica N. Borducchi et al. NATURE
- Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines?
- (2018) Nataschja I. Ho et al. Frontiers in Immunology
- Trial Watch: Toll-like receptor agonists in cancer immunotherapy
- (2018) Melody Smith et al. OncoImmunology
- Cutting Edge: A Dual TLR2 and TLR7 Ligand Induces Highly Potent Humoral and Cell-Mediated Immune Responses
- (2017) Alice Gutjahr et al. JOURNAL OF IMMUNOLOGY
- Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy
- (2017) Angela Tsai et al. JOURNAL OF VIROLOGY
- The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon
- (2017) A R Krarup et al. Mucosal Immunology
- Toll-like receptor 3 activation selectively reverses HIV latency in microglial cells
- (2017) David Alvarez-Carbonell et al. Retrovirology
- Mycobacterium tuberculosis reactivates latent HIV-1 in T cells in vitro
- (2017) Erica C. Larson et al. PLoS One
- Polyfunctional HIV-specific T cells in Post-Treatment Controllers
- (2016) Assia Samri et al. AIDS
- Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy
- (2016) Carolina Gutiérrez et al. AIDS
- TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells
- (2016) Rujuta A. Bam et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Drug-Free Zone—Lymph Nodes as a Safe Haven for HIV
- (2016) Anna Licht et al. Cell Host & Microbe
- Toll-like receptor-3 mediates HIV-1 transactivation via NFκB and JNK pathways and histone acetylation, but prolonged activation suppresses Tat and HIV-1 replication
- (2016) Biju Bhargavan et al. CELLULAR SIGNALLING
- A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+T Cells
- (2016) Rasmus Offersen et al. JOURNAL OF VIROLOGY
- Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV
- (2016) M. A. Rochat et al. JOURNAL OF VIROLOGY
- HIV DNA Is Frequently Present within Pathologic Tissues Evaluated at Autopsy from Combined Antiretroviral Therapy-Treated Patients with Undetectable Viral Loads
- (2016) Susanna L. Lamers et al. JOURNAL OF VIROLOGY
- Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys
- (2016) Erica N. Borducchi et al. NATURE
- Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+T cells
- (2016) Shu Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HIV-1 Eradication: Early Trials (and Tribulations)
- (2016) Adam M. Spivak et al. TRENDS IN MOLECULAR MEDICINE
- A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes
- (2016) R. Brad Jones et al. PLoS Pathogens
- Molecular Determinants of GS-9620-Dependent TLR7 Activation
- (2016) Indrani Rebbapragada et al. PLoS One
- Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious diseases
- (2015) C. Skevaki et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside
- (2015) Burghardt Wittig et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B
- (2015) Stephan Menne et al. JOURNAL OF HEPATOLOGY
- Synergistic Stimulation with Different TLR7 Ligands Modulates Gene Expression Patterns in the Human Plasmacytoid Dendritic Cell Line CAL-1
- (2015) Tobias Hilbert et al. MEDIATORS OF INFLAMMATION
- The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
- (2015) Ole S. Søgaard et al. PLoS Pathogens
- DAMPs from Cell Death to New Life
- (2015) Emilie Vénéreau et al. Frontiers in Immunology
- Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study
- (2015) Julian H Elliott et al. Lancet HIV
- Specific activation of the TLR1-TLR2 heterodimer by small-molecule agonists
- (2015) K. Cheng et al. Science Advances
- Double-Stranded RNA Induces an Antiviral Defense Status in Epidermal Keratinocytes through TLR3-, PKR-, and MDA5/RIG-I-Mediated Differential Signaling
- (2014) B. N. Kalali et al. JOURNAL OF IMMUNOLOGY
- X-Chromosome Complement and Estrogen Receptor Signaling Independently Contribute to the Enhanced TLR7-Mediated IFN-α Production of Plasmacytoid Dendritic Cells from Women
- (2014) Sophie Laffont et al. JOURNAL OF IMMUNOLOGY
- HIV-1 Expression Within Resting CD4+ T Cells After Multiple Doses of Vorinostat
- (2014) N. M. Archin et al. JOURNAL OF INFECTIOUS DISEASES
- Human TLR10 is an anti-inflammatory pattern-recognition receptor
- (2014) Marije Oosting et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunologic strategies for HIV-1 remission and eradication
- (2014) D. H. Barouch et al. SCIENCE
- Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy
- (2014) Julian H. Elliott et al. PLoS Pathogens
- Toll-Like Receptor Signaling Pathways
- (2014) Takumi Kawasaki et al. Frontiers in Immunology
- Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial
- (2014) Thomas A Rasmussen et al. Lancet HIV
- Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist
- (2013) Uri Lopatin et al. ANTIVIRAL THERAPY
- Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure
- (2013) Ya-Chi Ho et al. CELL
- A Pilot Study Assessing the Safety and Latency-Reversing Activity of Disulfiram in HIV-1-Infected Adults on Antiretroviral Therapy
- (2013) A. M. Spivak et al. CLINICAL INFECTIOUS DISEASES
- GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus in Chronically Infected Chimpanzees
- (2013) Robert E. Lanford et al. GASTROENTEROLOGY
- The Distribution of HIV DNA and RNA in Cell Subsets Differs in Gut and Blood of HIV-Positive Patients on ART: Implications for Viral Persistence
- (2013) Steven A. Yukl et al. JOURNAL OF INFECTIOUS DISEASES
- Administration of a Toll-Like Receptor 9 Agonist Decreases the Proviral Reservoir in Virologically Suppressed HIV-Infected Patients
- (2013) Anni A. Winckelmann et al. PLoS One
- Reactivation of latent HIV-1 in central memory CD4+ T cells through TLR-1/2 stimulation
- (2013) Camille L Novis et al. Retrovirology
- HIV-1 transcription and latency: an update
- (2013) Carine Van Lint et al. Retrovirology
- Comparison of HDAC inhibitors in clinical development
- (2013) Thomas Aagaard Rasmussen et al. Human Vaccines & Immunotherapeutics
- Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study
- (2013) Asier Sáez-Cirión et al. PLoS Pathogens
- Targeting Toll-Like Receptors: Promising Therapeutic Strategies for the Management of Sepsis-Associated Pathology and Infectious Diseases
- (2013) Athina Savva et al. Frontiers in Immunology
- Trial Watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study
- (2012) JP Routy et al. HIV MEDICINE
- Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation
- (2012) Liang Shan et al. IMMUNITY
- Antiviral applications of Toll-like receptor agonists
- (2012) N. J. Horscroft et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Proline-Proline-Glutamic Acid (PPE) Protein Rv1168c ofMycobacterium tuberculosisAugments Transcription from HIV-1 Long Terminal Repeat Promoter
- (2012) Khalid Hussain Bhat et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Latent HIV-1 Infection Occurs in Multiple Subsets of Hematopoietic Progenitor Cells and Is Reversed by NF- B Activation
- (2012) L. A. McNamara et al. JOURNAL OF VIROLOGY
- Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
- (2012) N. M. Archin et al. NATURE
- Modulating immunity as a therapy for bacterial infections
- (2012) Robert E. W. Hancock et al. NATURE REVIEWS MICROBIOLOGY
- Structural Basis of TLR5-Flagellin Recognition and Signaling
- (2012) S.-i. Yoon et al. SCIENCE
- Trial Watch
- (2012) Lorenzo Galluzzi et al. OncoImmunology
- Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
- (2012) Erika Vacchelli et al. OncoImmunology
- Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV
- (2011) J. F. Bergmann et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- IRF7: activation, regulation, modification and function
- (2011) S Ning et al. GENES AND IMMUNITY
- Pathogen Recognition by the Innate Immune System
- (2011) Himanshu Kumar et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- A TLR5 Agonist Inhibits Acute Renal Ischemic Failure
- (2011) N. Fukuzawa et al. JOURNAL OF IMMUNOLOGY
- Structure–Activity Relationships in Toll-Like Receptor 2-Agonists Leading to Simplified Monoacyl Lipopeptides
- (2011) Geetanjali Agnihotri et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Toll-Like Receptor 2 Pathway Establishes Colonization by a Commensal of the Human Microbiota
- (2011) J. L. Round et al. SCIENCE
- Three CpG oligodeoxynucleotide classes differentially enhance antigen-specific humoral and cellular immune responses in mice
- (2011) Ying Liu et al. VACCINE
- Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy
- (2010) Ole S Søgaard et al. AIDS
- Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection
- (2010) Laurent Hocqueloux et al. AIDS
- HIV-1 Reactivation Induced by the Periodontal Pathogens Fusobacterium nucleatum and Porphyromonas gingivalis Involves Toll-Like Receptor 4 and 9 Activation in Monocytes/Macrophages
- (2010) O. A. Gonzalez et al. Clinical and Vaccine Immunology
- Identification of Novel Synthetic Toll-like Receptor 2 Agonists by High Throughput Screening
- (2010) Yue Guan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Generation of Th1-Polarizing Dendritic Cells Using the TLR7/8 Agonist CL075
- (2010) S. Spranger et al. JOURNAL OF IMMUNOLOGY
- Human TLRs 10 and 1 Share Common Mechanisms of Innate Immune Sensing but Not Signaling
- (2010) Y. Guan et al. JOURNAL OF IMMUNOLOGY
- Flagellin as an Adjuvant: Cellular Mechanisms and Potential
- (2010) S. B. Mizel et al. JOURNAL OF IMMUNOLOGY
- The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
- (2010) Taro Kawai et al. NATURE IMMUNOLOGY
- Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+ Cell Infection
- (2010) Nancie M. Archin et al. PLoS One
- Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir
- (2009) Nathalie Sagot-Lerolle et al. AIDS
- Recognition of Lipopeptide Patterns by Toll-like Receptor 2-Toll-like Receptor 6 Heterodimer
- (2009) Jin Young Kang et al. IMMUNITY
- MyD88 Adapter-like (Mal)/TIRAP Interaction with TRAF6 Is Critical for TLR2- and TLR4-mediated NF-κB Proinflammatory Responses
- (2009) Brett Verstak et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Sex differences in the Toll-like receptor–mediated response of plasmacytoid dendritic cells to HIV-1
- (2009) Angela Meier et al. NATURE MEDICINE
- HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
- (2009) Nicolas Chomont et al. NATURE MEDICINE
- Long-Term Control of HIV byCCR5Delta32/Delta32 Stem-Cell Transplantation
- (2009) Gero Hütter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7
- (2009) Tomoko Hayashi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CL097, A TLR7/8 LIGAND, INHIBITS TLR-4-DEPENDENT ACTIVATION OF IRAK-M AND BCL-3 EXPRESSION
- (2009) Branka Petricevic et al. SHOCK
- TLR5 stimulation is sufficient to trigger reactivation of latent HIV-1 provirus in T lymphoid cells and activate virus gene expression in central memory CD4+ T cells
- (2009) Sandra Thibault et al. VIROLOGY
- Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells
- (2008) Nancy M Archin et al. AIDS
- TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-β
- (2008) Jonathan C Kagan et al. NATURE IMMUNOLOGY
- Anti-HIV Activity Mediated by Natural Killer and CD8+ Cells after Toll-Like Receptor 7/8 Triggering
- (2008) Erika Schlaepfer et al. PLoS One
- An Agonist of Toll-Like Receptor 5 Has Radioprotective Activity in Mouse and Primate Models
- (2008) L. G. Burdelya et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now